Hemostasis and aging

Critical Reviews in Oncology/Hematology

Volumn 60, Issue 2, 2006, Pages 144-151

  Franchini, Massimo ^a  

^a OSPEDALE POLICLINICO   (Italy)

Author keywords

Aging; Hemostasis; Thrombosis

Indexed keywords

ANGIOTENSIN II; ANTITHROMBIN; BETA THROMBOGLOBULIN; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; D DIMER; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBRINOGEN; HEPARIN COFACTOR II; HIGH MOLECULAR WEIGHT KININOGEN; NITRIC OXIDE; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREKALLIKREIN; PROSTACYCLIN; PROTEIN C; PROTEIN S; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR; VON WILLEBRAND FACTOR;

AGING; BLEEDING TIME; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; ENVIRONMENTAL FACTOR; FAT INTAKE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; GENETIC POLYMORPHISM; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOSIS; VASCULAR ENDOTHELIUM; VEIN THROMBOSIS;

EID: 33750996725     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2006.06.004     Document Type: Review

References (110)

1. Abbate R., Prisco D., Rostagno C., Boddi M., and Gensini G.F. Age-related changes in the hemostatic system. Int J Clin Lab Res 23 (1993) 1-3
2. Sane D.C. Aging and coagulation. Clin Adv Hematol Oncol 1 (2003) 583-584
3. Wilkerson W.R., and Sane D.C. Aging and thrombosis. Sem Thromb Hemost 28 (2002) 555-567
4. Barzilai N., and Shuldiner A.R. Searching for human longevity genes: the future history of gerontology in the post-genomic era. J Gerontol 56 (2001) 83-87
5. Sagripanti A., and Carpi A. Natural anticoagulants, aging, and thromboembolism. Exp Gerontol 33 (1998) 891-896
6. Balleisen L., Bailey J., Epping P.H., Schulte H., and van de Loo J. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population. I. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause. Thromb Haemost 54 (1985) 475-479
7. Hager K., Setzer J., Vogl T., Voit J., and Platt D. Blood coagulation factors in the elderly. Arch Gerontol Geriatr 9 (1989) 277-282
8. Ofosu F.A., Craven S., Dewar L., Anvari N., Andrew M., and Blajchman M.A. Age-related changes in factor VII proteolysis in vivo. Br J Haematol 94 (1996) 407-412
9. Lowe G.D., Rumley A., Woodward M., et al. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use. Br J Haematol 97 (1997) 775-784
10. Cooperberg A.A., and Teitelbaum J. The concentration of antihaemophilic globulin (AHG) related to age. Br J Haematol 6 (1960) 281-287
11. Preston A.E., and Barr A. The plasma concentration of factor VIII in the normal population. II. The effects of age, sex and blood group. Br J Haematol 10 (1964) 238-245
12. Hamilton P.J., Allardyce M., Ogston D., Dawson A.A., and Douglas A.S. The effect of age upon the coagulation system. J Clin Pathol 27 (1974) 980-982
13. Meade T.W., North W.R., Chakrabarti R., Haines A.P., and Stirling Y. Population-based distributions of haemostatic variables. Br Med Bull 33 (1977) 283-288
14. Meade T.W., Chakrabarti R., Haines A.P., North W.R., and Stirling Y. Characteristics affecting fibrinolytic activity and plasma fibrinogen concentrations. Br Med J 1 (1979) 153-156
15. Brozovic M., Chakrabarti R., Stirling Y., Fenton S., North W.R., and Meade T.W. Factor V in an industrial population. Br J Haematol 33 (1976) 543-550
16. Kannel W.B., Wolf P.A., Castelli W.P., and D'Agostino R.B. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 258 (1987) 1183-1186
17. Stone M.C., and Thorpe J.M. Plasma fibrinogen - a major coronary risk factor. J R Coll Gen Pract 35 (1985) 565-571
18. Wilhelmsen L., Svardsudd K., Korsan-Bengtsen K., Larsson B., Welin L., and Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 31 (1984) 501-505
19. Tracy R.P., Bovill E.G., Fried L.P., et al. The distribution of coagulation factors VII and VIII and fibrinogen in adults over 65 years. Results from the Cardiovascular Health Study. Ann Epidemiol 2 (1992) 509-519
20. Gulledge A.A., Rezaee F., Verheijen J.H., and Lord S.T. A novel transgenic mouse model of hyperfibrinogenemia. Thromb Haemost 86 (2001) 511-516
21. Tracy R.P., and Bovill E.G. Thrombosis and cardiovascular risk in the elderly. Arch Pathol Lab Med 16 (1992) 1307-1312
22. Tracy R.P. Hemostatic and inflammatory markers as risk factors for coronary disease in the elderly. Am J Geriatr Cardiol 11 (2002) 93-100
23. Ershler W.B. Interleukin-6: a cytokine for gerontologists. J Am Geriatr Soc 41 (1993) 176-181
24. Köster T., Blann A.D., Briet E., Vandenbroucke J.P., and Rosendaal F.R. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345 (1995) 152-155
25. Conlan M.G., Folsom A.R., Finch A., et al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 70 (1993) 380-385
26. Howard P.R., Bovill E.G., Pike J., Church W.R., and Tracy R.P. Factor VII antigen levels in a healthy blood donor population. Thromb Haemost 72 (1994) 21-27
27. Junker R., Heinrich J., Schulte H., van de Loo J., and Assmann G. Coagulation factor VII and the risk of coronary heart disease in healthy men. Arterioscler Thromb Vasc Biol 17 (1997) 1539-1544
28. Tracy R.P., Arnold A.M., Ettinger W., Fried L., Meilahn E., and Savage P. The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: results from the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 19 (1999) 1776-1783
29. Bauer K.A., Weiss L.M., Sparrow D., Vokonas P.S., and Rosenberg R.D. Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study. J Clin Invest 80 (1987) 1527-1534
30. Bauer K.A., Kass B.L., ten Cate H., Bednarek M.A., Hawiger J.J., and Rosenberg R.D. Detection of factor X activation in humans. Blood 74 (1989) 2007-2015
31. Bauer K.A., Kass B.L., ten Cate H., Hawiger J.J., and Rosenberg R.D. Factor IX is activated in vivo by the tissue factor mechanism. Blood 76 (1990) 731-736
32. Mari D., Mannucci P.M., Coppola R., Bottasso B., Bauer K.A., and Rosenberg R.D. Hypercoagulability in centenarians: the paradox of successful aging. Blood 85 (1995) 3144-3149
33. Cadroy Y., Pierrejean D., Fontan B., Sie P., and Boneu B. Influence of aging on the activity of the hemostatic system: prothrombin fragment 1 + 2, thrombin-antithrombin III complexes and D-dimers in 80 healthy subjects with age ranging from 20 to 94 years. Nouv Rev Fr Hematol 34 (1992) 43-46
34. Coppola R., Mari D., Lattuada A., and Franceschi C. von Willebrand factor in Italian centenarians. Haematologica 88 (2003) 39-43
35. Sweeney J.D., and Hoerning L.A. Age dependent effect on the level of factor IX. Am J Clin Pathol 99 (1993) 687-688
36. Ariens R.A., Kohler H.P., Mansfield M.W., and Grant P.J. Subunit antigen and activity levels of blood coagulation factor XIII in healthy individuals. Relation to sex, age, smoking, and hypertension. Arterioscler Thromb Vasc Biol 19 (1999) 2012-2016
37. Dolan G., Neal K., Cooper P., Brown P., Preston F.E., and Protein C. Antithrombin III and plasminogen: effect of age, sex and blood group. Br J Haematol 86 (1994) 798-803
38. Tait R.C., Walker I.D., Islam S.I., et al. Influence of demographic factors on antithrombin III activity in a healthy population. Br J Haematol 84 (1993) 476-480
39. Stout R.W., Crawford V.L., McDermott M.J., Rocks M.J., and Morris T.C. Seasonal changes in haemostatic factors in young and elderly subjects. Age Ageing 25 (1996) 256-258
40. Cadroy Y., Daviaud P., Saivin S., Sie P., and Boneu B. Distribution of 16 hemostatic laboratory variables assayed in 100 blood donors. Nouv Rev Fr Hematol 32 (1990) 259-264
41. Sakkinen P.A., Cushman M., Psaty B.M., et al. Correlates of antithrombin, protein C, protein S, and TFPI in a healthy elderly cohort. Thromb Haemost 80 (1998) 134-139
42. Ariens R.A., Coppola R., Potenza I., and Mannucci P.M. The increase with age of the components of the tissue factor coagulation pathway is gender-dependent. Blood Coagul Fibrin 6 (1995) 433-437
43. Kario K., Matsuo T., and Kobayashi H. Heparin cofactor II deficiency in the elderly: comparison with antithrombin III. Thromb Res 66 (1992) 489-498
44. Hamilton P.J., Dawson Audrey A., Ogston D., and Douglas A.S. The effect of age on the fibrinolytic enzyme system. J Clin Pathol 27 (1974) 326-329
45. Gleerup G., and Winther K. The effect of ageing on platelet function and fibrinolytic activity. Angiology 46 (1995) 715-718
46. Mehta J., Mehta P., Lawson D., and Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. J Am Coll Cardiol 9 (1987) 263-268
47. Eren M., Painter C.A., Atkinson J.B., Declerck P.J., and Vaughan D.E. Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation 106 (2002) 491-496
48. Yamamoto K., Shimokawa T., Yi H., et al. Aging accelerates endotoxin-induced thrombosis: increased responses of plasminogen activator inhibitor-1 and lipopolysaccharide signaling with aging. Am J Pathol 161 (2002) 1805-1814
49. Cushman M., Lemaitre R.N., Kuller L.H., et al. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 19 (1999) 493-498
50. Yamamoto K., Takeshita K., Shimokawa T., et al. Plasminogen activator inhibitor-1 is a major stress-regulated gene: implications for stress-induced thrombosis in aged individuals. Proc Natl Acad Sci USA 99 (2002) 890-895
51. Yamamoto K., Takeshita K., Kojima T., Takamatsu J., and Saito H. Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly. Cardiovasc Res 66 (2005) 276-285
52. Sakkinen P.A., Cushman M., Psaty B.M., et al. Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women. Arterioscler Thromb Vasc Biol 19 (1999) 499-504
53. Schatteman K.A., Goossens F.J., Scharpe S.S., Neels H.M., and Hendriks D.F. Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade, in human plasma. Clin Chem 45 (1999) 807-813
54. Jørgensen K.A., Dyerberg J., Olesen A.S., and Stoffersen E. Acetylsalicylic acid, bleeding time and age. Thromb Res 19 (1980) 799-805
55. Zahavi J., Jones N.A., Leyton J., Dubiel M., and Kakkar V.V. Enhanced in vivo platelet "release reaction" in old healthy individuals. Thromb Res 17 (1980) 329-336
56. Kasjanovova D., and Balaz V. Age-related changes in human platelet function in vitro. Mech Ageing Dev 37 (1986) 175-182
57. Bastyr III E.J., Kadrofske M.M., and Vinik A.I. Platelet activity and phosphoinositide turnover increase with advancing age. Am J Med 88 (1990) 601-606
58. Reilly I.A., and FitzGerald G.A. Eicosenoid biosynthesis and platelet function with advancing age. Thromb Res 41 (1986) 545-554
59. Brandes R.P., Fleming I., and Busse R. Endothelial aging. Cardiovasc Res 66 (2005) 286-294
60. Lakatta E.G., Mitchell J.H., Pomerance A., and Rowe G.G. Human aging: changes in structure and function. J Am Coll Cardiol 10 2 Suppl. A (1987) 42A-47A
61. Feyzi E., Saldeen T., Larsson E., Lindahl U., and Salmivirta M. Age-dependent modulation of heparan sulfate structure and function. J Biol Chem 273 (1998) 13395-13398
62. Taddei S., Virdis A., Ghiadoni L., et al. Age-related reduction of NO availability and oxidative stress in humans. Hypertension 38 (2001) 274-279
63. Celermajer D.S., Sorensen K.E., Bull C., Robinson J., and Deanfield J.E. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 24 (1994) 1468-1474
64. Celermajer D.S., Sorensen K.E., Spiegelhalter D.J., Georgakopoulos D., Robinson J., and Deanfield J.E. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol 24 (1994) 471-476
65. Chou T.C., Yen M.H., Li C.Y., and Ding Y.A. Alterations of nitric oxide synthase expression with aging and hypertension in rats. Hypertension 31 (1998) 643-648
66. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res. 88 (2001) 756-762
67. Garg U.C., and Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 83 (1989) 1774-1777
68. Timiras P. Changing regulation of vascular endothelium with aging. Int Med 29 (1997) 129-138
69. Wang M., Takagi G., Asai K., et al. Aging increases aortic MMP-2 activity and angiotensin II in nonhuman primates. Hypertension 41 (2003) 1308-1316
70. Heymes C., Silvestre J.S., Llorens-Cortes C., et al. Cardiac senescence is associated with enhanced expression of angiotensin II receptor subtypes. Endocrinology 139 (1998) 2579-2587
71. Bonfigli A.R., Sirolla C., Cenerelli S., et al. Plasminogen activator inhibitor-1 plasma level increases with age in subjects with the 4G allele at position -675 in the promoter region. Thromb Haemost 92 (2004) 1164-1165
72. Mannucci P.M., Mari D., Merati G., et al. Gene polymorphisms predicting high plasma levels of coagulation and fibrinolysis proteins. A study in centenarians. Arterioscler Thromb Vasc Biol 17 (1997) 755-759
73. Mari D., Mannucci P.M., Duca F., Bertolini S., and Franceschi C. Mutant factor V (Arg506Gln) in healthy centenarians. Lancet 347 (1996) 1044
74. Sacchi E., Duca F., Franceschi C., and Mari D. Prothrombin gene mutation (G20210A) in healthy centenarians. Thromb Haemost 81 (1999) 990-991
75. Faure-Delanef L., Quere I., Zouali H., and Cohen D. Human longevity and R506Q factor V gene mutation. Thromb Haemost 78 (1997) 1160
76. Kristensen S.R., Andersen-Ranberg K., Bathum L., and Jeune B. Factor V Leiden and venous thrombosis in Danish centenarians. Thromb Haemost 80 (1998) 860-861
77. Bladbjerg E.M., Andersen-Ranberg K., de Maat M.P., et al. Longevity is independent of common variations in genes associated with cardiovascular risk. Thromb Haemost 82 (1999) 1100-1105
78. Tan Q., Yashin A.I., Bladbjerg E.M., et al. Variations of cardiovascular disease associated genes exhibit sex-dependent influence on human longevity. Exp Gerontol 36 (2001) 1303-1315
79. Lottermoser K., Dusing R., Ervens P., et al. The plasminogen activator inhibitor 1 4G/5G polymorphism is not associated with longevity: a study in octogenarians. J Mol Med 79 (2001) 289-293
80. Meiklejohn D.J., Riches Z., Youngson N., and Vickers M.A. The contribution of factor VII gene polymorphisms to longevity in Scottish nonagenarians. Thromb Haemost 83 (2000) 519
81. Hessner M.J., Dinauer D.M., Kwiatkowski R., Neri B., and Raife T.J. Age-dependent prevalence of vascular disease-associated polymorphisms among 2689 volunteer blood donors. Clin Chem 47 (2001) 1879-1884
82. Matsushita S., Muramatsu T., Arai H., Matsui T., and Higuchi S. The frequency of the methylenetetrahydrofolate reductase-gene mutation varies with age in the normal population. Am J Hum Gen 61 (1997) 1459-1460
83. Todesco L., Angst C., Litynski P., Loehrer F., Fowler B., and Haefeli W.E. Methylenetetrahydrofolate reductase polymorphism, plasma homocysteine and age. Eur J Clin Invest 29 (1999) 1003-1009
84. Faure-Delanef L., Quere I., Chasse J.F., et al. Methylenetetrahydrofolate reductase thermolabile variant and human longevity. Am J Hum Genet 60 (1997) 999-1001
85. Harmon D.L., McMaster D., Shields D.C., Whitehead A.S., and Rea I.M. MTHFR thermolabile genotype frequencies and longevity in Northern Ireland. Atherosclerosis 131 (1997) 137-138
86. Rea I.M., McMaster D., Woodside J.V., et al. Community-living nonagenarians in Northern Ireland have lower plasma homocysteine but similar methylenetetrahydrofolate reductase thermolabile genotype prevalence compared to 70-89-year-old subjects. Atherosclerosis 149 (2000) 207-214
87. Brattstrom L., Zhang Y., Hurtig M., et al. A common methylenetetrahydrofolate reductase gene mutation and longevity. Atherosclerosis 141 (1998) 315-319
88. Rees D.C., Liu Y.T., Cox M.J., Elliott P., and Wainscoat J.S. Factor V Leiden and thermolabile methylenetetrahydrofolate reductase in extreme old age. Thromb Haemost 78 (1997) 1357-1359
89. Panza F., D'Introno A., Colacicco A.M., et al. Vascular genetic factors and human longevity. Mech Ageing Dev 125 (2004) 169-178
90. Schachter F., Faure-Delanef L., Guenot F., et al. Genetic associations with human longevity at the APOE and ACE loci. Nat Genet 6 (1994) 29-32
91. Louhija J., Miettinen H.E., Kontula K., Tikkanen M.J., Miettinen T.A., and Tilvis R.S. Aging and genetic variation of plasma apolipoproteins. Relative loss of the apolipoprotein E4 phenotype in centenarians. Arterioscler Thromb 14 (1994) 1084-1089
92. Panza F., Solfrizzi V., Torres F., et al. Decreased frequency of apolipoprotein E epsilon4 allele from Northern to Southern Europe in Alzheimer's disease patients and centenarians. Neurosci Lett 277 (1999) 53-56
93. Kurachi S., Deyashiki Y., Takeshita J., and Kurachi K. Genetic mechanisms of age regulation of human blood coagulation factor IX. Science 285 (1999) 739-743
94. Zhang K., Kurachi S., and Kurachi K. Genetic mechanisms of age regulation of protein C and blood coagulation. J Biol Chem 277 (2002) 4532-4540
95. Hanon O., Luong V., Mourad J.J., Bortolotto L.A., Jeunemaitre X., and Girerd X. Aging, carotid artery distensibility, and the Ser422Gly elastin gene polymorphism in humans. Hypertension 38 (2001) 1185-1189
96. Lajemi M., Labat C., Gautier S., et al. Angiotensin II type 1 receptor-153A/G and 1166A/C gene polymorphisms and increase in aortic stiffness with age in hypertensive subjects. J Hypertens 19 (2001) 407-413
97. Allman-Farinelli M.A., and Dawson B. Diet and aging: bearing on thrombosis and hemostasis. Semin Thromb Hemost 31 (2005) 111-117
98. Kris-Etherton P.M., Harris W.S., Appel L.J., and Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Arterioscler Thromb Vasc Biol 23 (2003) e20-e31
99. Allman-Farinelli M.A., Hall D., Kingham K., Pang D., Petocz P., and Favaloro E.J. Comparison of the effects of two low fat diets with different alpha-linolenic:linoleic acid ratios on coagulation and fibrinolysis. Atherosclerosis 142 (1999) 159-168
100. Smith R.D., Kelly C.N., Fielding B.A., et al. Long-term monounsaturated fatty acid diets reduce platelet aggregation in healthy young subjects. Br J Nutr 90 (2003) 597-606
101. Lopez-Segura F., Velasco F., Lopez-Miranda J., et al. Monounsaturated fatty acid-enriched diet decreases plasma plasminogen activator inhibitor type 1. Arterioscler Thromb Vasc Biol 16 (1996) 82-88
102. Juhan-Vague I., Alessi M.C., Mavri A., and Morange P.E. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 1 (2003) 1575-1579
103. Liu S., and Willet W. Dietary glycemic load and atherothrombotic risk. Curr Atheroscler Rep 4 (2002) 454-461
104. Goldberg I.J., Mosca L., Piano M.R., and Fisher E.A. AHA Science Advisory. Wine and your heart: a science advisory for healthcare professionals from the Nutrition Committee, Council on Epidemiology and Prevention, and Council on Cardiovascular Nursing of the American Heart Association. Stroke 32 (2001) 591-594
105. Boushey C.J., Beresford S.A., Omenn G.S., and Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274 (1995) 1049-1057
106. Wannamethee S.G., Lowe G.D., Whincup P.H., Rumley A., Walker M., and Lennon L. Physical activity and hemostatic and inflammatory variables in elderly men. Circulation 105 (2002) 1785-1790
107. Mestries J.-C., Kruithof E.K., Gascon M.P., Herodin F., Agay D., and Ythier A. In vivo modulation of coagulation and fibrinolysis by recombinant glycosylated human interleukin-6 in baboons. Eur Cytokine Netw 5 (1994) 275-281
108. Niessen R.W., Lamping R.J., Jansen P.M., et al. Antithrombin acts as a negative acute phase protein as established with studies on HepG2 cells and in baboons. Thromb Haemost 78 (1997) 1088-1092
109. Cohen H.J., Harris T., and Pieper C.F. Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am J Med 114 (2003) 180-187
110. Meroni P.L., Mari D., Monti D., et al. Anti-beta 2 glycoprotein I antibodies in centenarians. Exp Gerontol 39 (2004) 1459-1465